Nkcfo LLC Purchases Shares of 375 United Therapeutics Co. (NASDAQ:UTHR)

Nkcfo LLC acquired a new position in United Therapeutics Co. (NASDAQ:UTHR) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 375 shares of the biotechnology company’s stock, valued at approximately $132,000.

Several other institutional investors have also recently made changes to their positions in UTHR. Milestone Asset Management LLC grew its holdings in United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 1,037 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of United Therapeutics by 9.1% during the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after acquiring an additional 789 shares during the last quarter. JPMorgan Chase & Co. grew its stake in United Therapeutics by 35.4% during the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after acquiring an additional 50,291 shares in the last quarter. Franklin Resources Inc. lifted its stake in United Therapeutics by 97.7% in the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Finally, Burney Co. boosted its holdings in shares of United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock valued at $8,441,000 after purchasing an additional 12,705 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other news, Director Nilda Mesa sold 255 shares of the stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $896,950.62. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 121,864 shares of company stock worth $44,516,965. Insiders own 11.90% of the company’s stock.

United Therapeutics Stock Up 0.0 %

Shares of United Therapeutics stock opened at $370.58 on Friday. The stock’s fifty day moving average is $361.93 and its two-hundred day moving average is $358.80. United Therapeutics Co. has a 52 week low of $211.61 and a 52 week high of $417.82. The company has a market capitalization of $16.55 billion, a PE ratio of 16.27, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. TD Cowen increased their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. LADENBURG THALM/SH SH lifted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $382.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.